Skip to content
Vosevi(voxilaprevir)
Vosevi (voxilaprevir) is a small molecule pharmaceutical. Voxilaprevir was first approved as Vosevi on 2017-07-18. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Vosevi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sofosbuvir
+
Velpatasvir
+
Voxilaprevir
Tradename
Company
Number
Date
Products
VOSEVIGilead SciencesN-209195 RX2017-07-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
voseviNew Drug Application2019-11-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatitis c—D006526B19.2
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Sofosbuvir / Velpatasvir / Voxilaprevir, Vosevi, Gilead Sciences Inc
109128142037-06-01DP
113380072037-06-01DPU-2039, U-2040
92967822034-07-17DS, DP
111167832034-01-30DPU-2039, U-2040
85751352032-11-16DS, DPU-2039, U-2040
89213412032-11-16DS, DPU-2039, U-2040
89407182032-11-16DS, DPU-2039, U-2040
98687452032-11-16DS, DP
86180762030-12-11DS, DPU-2039, U-2040
92843422030-09-13DS, DPU-2039, U-2040
79645802029-03-26DS, DPU-2039, U-2040
86333092029-03-26DS, DPU-2039, U-2040
88891592029-03-26DS, DPU-2039, U-2040
83342702028-03-21DS, DPU-2039, U-2040
85807652028-03-21DS, DPU-2039, U-2040
87353722028-03-21DS, DPU-2039, U-2040
89570462028-03-21U-2039, U-2040
90855732028-03-21DS, DPU-2039, U-2040
95859062028-03-21DS, DPU-2039, U-2040
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AP: Antivirals for treatment of hcv infections
— J05AP56: Sofosbuvir, velpatasvir and voxilaprevir
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I21—133—7
Peripheral arterial diseaseD058729EFO_0004265——13—4
Coronary artery diseaseD003324I25.1———1—1
Peripheral vascular diseasesD016491EFO_0003875I73.9———1—1
Diabetes mellitusD003920EFO_0000400E08-E13———1—1
Healthy volunteers/patients————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtherosclerosisD050197EFO_0003914I25.1—13——4
Myocardial ischemiaD017202EFO_1001375I20-I25—11——2
StrokeD020521EFO_0000712I63.9——2——2
IschemiaD007511EFO_0000556——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral infarctionD002544I63—1———1
HivD006678O98.711———1
Coronary diseaseD003327—1———1
Arterial occlusive diseasesD001157EFO_0009085—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute coronary syndromeD054058EFO_00056721————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVOXILAPREVIR
INNvoxilaprevir
Description
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.
Classification
Small molecule
Drug classantivirals: serine protease inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@H]1[C@@H](C(=O)N[C@]2(C(=O)NS(=O)(=O)C3(C)CC3)C[C@H]2C(C)C)N2C[C@@H]1Oc1nc3cc(OC)ccc3nc1C(F)(F)CCCC[C@@H]1C[C@H]1OC(=O)N[C@@H](C(C)(C)C)C2=O
Identifiers
PDB—
CAS-ID1535212-07-7
RxCUI1939323
ChEMBL IDCHEMBL3707372
ChEBI ID—
PubChem CID89921642
DrugBankDB12026
UNII ID0570F37359 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vosevi - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 683 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vosevi
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
188 adverse events reported
View more details